July 25th Options Now Available For AstraZeneca (AZN)

Analysis of AstraZeneca (AZN) options reveals potential strategies for investors seeking yield enhancement. Selling the $71 put offers a 3.50% annualized YieldBoost with a 61% chance of expiring worthless, while a covered call strategy at the $74 strike could yield a 5.33% annualized return, with a 56% chance of the contract expiring worthless; both options exhibit an implied volatility of approximately 25% compared to the stock's 23% trailing twelve month volatility.

Analysis

The article details two specific options strategies for AstraZeneca (AZN) shares, which currently trade at $72.62. For investors considering initiating a long position, selling the $71.00 strike put contract, with a current bid of 34 cents, offers a potential entry point at an effective cost basis of $70.66 if assigned. This represents an approximate 2% discount to the prevailing market price. Analytical data suggests a 61% probability of this out-of-the-money put expiring worthless; should this occur, it would yield a 0.48% return on the cash commitment, translating to an annualized YieldBoost of 3.50%. Alternatively, for existing AZN shareholders, selling the $74.00 strike call contract as a covered call, with a current bid of 53 cents, presents an income-generating opportunity. If AZN shares are called away at the July 25th expiration, this strategy would result in a total return of 2.63% (excluding dividends) from the current price level. There is an estimated 56% probability of this call expiring worthless, in which case the collected premium would represent a 0.73% boost to returns, or an annualized YieldBoost of 5.33%. Both options strategies exhibit an implied volatility of approximately 25%, slightly above AZN's trailing twelve-month actual volatility of 23%. The general sentiment for these option plays is characterized as mildly positive (sentiment score 0.35), with an inherently speculative tone.

Key Decisions for Investors

• Investors interested in acquiring AstraZeneca shares at a lower effective cost basis could consider selling the $71.00 strike put, which offers a potential entry at $70.66 or a 3.50% annualized yield if the option expires worthless.
• Current AstraZeneca shareholders seeking to generate additional income might evaluate selling the $74.00 strike covered call, which provides a 5.33% annualized YieldBoost if it expires worthless, while acknowledging the cap on potential upside if the stock price significantly appreciates beyond $74.00.
• The modest premium of implied volatility (25%) over AZN's historical volatility (23%) suggests a slightly more favorable environment for option sellers, but this should be weighed against the inherent risks of options trading and the stock's specific outlook.
• Given the speculative nature of these options strategies, investors should carefully consider the stated probabilities of expiration and align these approaches with their broader investment thesis for AstraZeneca and overall risk tolerance.